Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

GPC Biotech and Agennix announce proposed merger
March 2009
SHARING OPTIONS:

MUNICH, Germany—GPC Biotech AG and Agennix Inc. announced last month that the two oncology-focused biotechnology companies have signed a merger agreement. In the transaction, GPC Biotech is to be merged into a new German company which will hold all of Agennix's shares Agennix and a €15 million cash contribution by dievini Hopp BioTech holding GmbH & Co. KG, an investment company of Dietmar Hopp, co-founder of SAP and one of the largest shareholders of GPC Biotech. The merger combines GPC Biotech's and Agennix's oncology pipelines, including Agennix's Phase III novel oncology therapy, talactoferrin, with the clinical development and financial resources of GPC Biotech and dievini Hopp BioTech holding. The proposed merger is subject to the approval of the shareholders' meetings of both GPC Biotech and the new company and further closing conditions, including any antitrust clearances. If approved, the merger is expected to be completed by the end of this year.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.